ReviewFrontiers in oncology2026
Artificial intelligence-assisted photodynamic diagnosis and photodynamic therapy against cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) comprises advanced computational systems designed to simulate selected aspects of human cognitive functions, such as learning, reasoning, and perception. While AI does not fully replicate human cognition, its analytical processing of large datasets through "machine learning (ML)" and "deep learning (DL)" has increasingly been applied in medicine, including photodynamic diagnosis (PDD) and photodynamic therapy (PDT). In oncology, these modalities are increasingly used for early cancer detection, tumor margin delineation, and personalized therapeutic planning. These applications involve AI-PDD/PDT workflows, dosimetry, predictive modeling, and translational opportunities across Western and Chinese medicine. The working process of AI-PDD/PDT systems encompasses treatment workflows, dosimetry optimization, real-time monitoring, and outcome prediction. AI-driven systems standardize photosensitizer preparation, reduce human error, and enhance reproducibility in PDT. Findings are synthesized conceptually across diverse studies, focusing on thematic integration of AI-assisted PDD/PDT mechanisms rather than quantitative pooling or statistical comparison of outcomes. Cancer applications include bladder, gastric, colorectal, and breast tumors, where AI-PDD/PDT improves diagnostic precision and enhances therapeutic efficacy. The rapid development of AI in recent years has extended into PDT, supporting fundamental research, clinical translation, and therapeutic innovation. AI-PDD/PDT demonstrates potential to enhance accuracy, safety, and efficiency through workflow optimization and predictive modeling. However, current evidence remains preliminary, and further systematic validation and clinical trials are required to substantiate these proposed benefits. Future milestones include refining the interface between AI and PDD/PDT and conducting prospective, multicenter trials to establish clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.